Launch and Commercialisation
”We take the pain out of outsourcing and help you from strategic consultancy to high quality delivery. Leverage our deep understanding of launch and commercialisation projects and our reputation for quality delivery to maximise commercial success and market impact for bio-pharma products.
Pharmaceutical and biotech companies are facing increasing market pressure to get new products to market faster than ever. Even after achieving regulatory approval, there are no guarantees of patient access and commercial success. In fact, streamlined regulatory data packages may even make it harder to ensure all patients can benefit from a new therapy.
Strategically focused for commercial success and market adoption
We here at Veramed understand that both ‘Launch’ and ‘Commercialisation’ bring their own challenges and strategic needs. We will support you with a range of strategically-focused and collaborative services that help maximise launch impact and commercial success. Whether you want to get strategic advice years before launch or execute specific tactics like publications, we help you meet your goals and strategic needs all the way through to long-term patient or end-buyer adoption.
We will help your team avoid the common pitfalls, safeguarding you from mistakes many bio-pharma companies make during product launch and commercialisation. Discover more about our process below.
What we can provide
We provide a range of services to ensure that you meet your strategic objectives and achieve commercial success.
- Real World Evidence (RWE)
- Strategic evidence planning
- Publication planning
- Data mining
- HTA submissions
- Customer interactions
Real World Evidence
We develop high-quality observational studies – both prospective and retrospective – to complement clinical trials with real-world data. Our expertise in both pre-launch and post-launch observational research will serve your evidence needs across patients, physicians and payers.
Strategic Evidence Planning
Leverage our expertise across different companies and therapeutic areas to provide outstanding advice about when you want to communicate certain evidence, in a certain format and to which customers so you can optimally plan your data generation solutions accordingly. Our team helps you to identify and fill strategic evidence gaps, and optimise the communication of the benefits and risks of a new therapy.
We partner with you to develop a keen understanding of how your new therapy fits into the existing medical landscape based on your company’s internal and competitive intelligence data. This is an in-depth, collaborative process that considers the needs of patients, physicians, and payers.
Publication planning
Based on the strategic pillars of your compound, we develop and execute publication plans with you, customised to your processes. Based on our experience with hundreds of publications across various therapeutic areas, we not only help you to write the publications, we also suggest additional publication ideas to optimise the communication around your asset.
We align these suggestions with the compound specific strategic needs of your product. We provide high-quality data visualizations to engage audiences and communicate key take-aways effectively.
Data Mining
Our data mining and network meta-analysis services maximise the value of existing internal or external data. Leverage your existing data to maximize the value for a sponsor’s internal understanding of the data and communications to patients, physicians, and payers. We provide customised solutions to understand your data. Instead of screening through hundreds of static tables, explore your data easily and find key findings via interactive visual tools.
HTA submission
Maximise the opportunity of successful HTA submissions. Our experience with HTA submissions on a global scale will help you to prepare HTA dossiers efficiently and to the highest quality. We help you leverage internal and external data to get the key messages across to payers and explain these in payer facing interactions like the German GBA hearing.
HTA submissions – especially in Germany and the UK – require knowledge of the processes, excellent communication skills in local language, and flexible high-quality deliverables. Our unique insights and experience allow us to create customised local language deliverables efficiently and of the highest quality.
Customer interactions
Ensure high quality interactions with all your external customers including key opinion leaders (KOLs), practicing physicians, key accounts, and patients. We attend or help you attend advisory boards with KOLs to optimise the understanding and communication of data. We train your internal customer facing teams (medical scientific liasons and other) to communicate data with quality.
Maximising launch impact
At launch, there is only one chance to get it right and many obstacles to derail success.
Our experience in successfully launching products on both a global and local level means we’re able to address any pitfalls or challenges your team is facing long before going to market through close collaboration and strategic evidence planning. Our approach includes evaluating additional sources of evidence from clinical trials, real-world evidence, data mining/network meta-analysis and more.
Once launched, we help develop an optimal communication stream of your data to patients, payers, and physicians, which can then be better shared with your company internally.
We collaborate not only with the traditional internal stakeholders of statistics and data science – medical and pricing, re-reimbursement, and access – but also with marketing, medical information/education and sales.
Upcoming webinar
9 strategic insights you get from a great medical affairs statistician
Wed, Sep 21, 2022 · 4:00 PM London (GMT +1:00)
What’s your experience of working with Statisticians in medical affairs?
Do they only deliver the tables you asked for?
Do they share why they can’t deliver what you asked for?
Do you struggle to receive the analyses you need in time?
In our latest webinar, Alexander Schacht, EVP of Launch and Commercialization Data Sciences at Vermed, discusses the integral role Statisticians have in helping build a world class medical affairs team.
Alexander will reflect on his 20 years of experience working in medical affairs, and use first-hand case studies to provide 9 strategic insights you can garner from a great medical affairs Statistician.

Webinar Catch-up
Our latest webinar, ‘9 strategic insights you get from a great medical affairs statistician’ is now available.
To view all previous webinar recordings, simply click here.
Data driven
Our vision is to provide company internal and external stakeholders with the right data at the right time to make the right decisions. This ranges from understanding the clinical and real-world data to building a strategic evidence plan and data mining of your internal data sources.
Passion and Expertise
As a people-focused CRO, we’re passionate about delivering high-quality, on time deliverables that ensure new remedies get to the market faster. Our expert team brings years of experience and that ‘Veramed touch’ to the table, focusing on close collaboration and effective planning to help you through launch and commercialisation.
Comprehensive support
We provide the right support, built and delivered through a collaborative, trusting relationship. This close collaboration help create an effective launch strategy on time, as well as commercialisation plan that maximises ROI and market traction.
Get in touch
CONTACTHave you found what you are looking for? Learn more about our other services below or get in touch.